OncoMatch/Clinical Trials/NCT06839144
Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression
Is NCT06839144 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Propranolol (Beta-Blocker) and Etodolac (COX-2 Inhibitor) for ovarian cancer.
Treatment: Propranolol (Beta-Blocker) and Etodolac (COX-2 Inhibitor) — This study investigates the impact of perioperative inhibition of beta-adrenergic and COX-2 signaling in ovarian cancer patients undergoing debulking surgery. The trial aims to assess the feasibility, safety, and biological effects of a combination of propranolol and etodolac in reducing cancer metastasis and improving immune responses.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Ovarian Cancer
Disease stage
Metastatic disease required
Ovarian Cancer Metastatic Recurrent
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Lab requirements
Kidney function
renal failure, measured by creatinine level >1.5
Liver function
significant liver dysfunction (known cirrhosis, Bilirubin level>2)
Cardiac function
significant heart failure (NYHA functional class 3 or Higher); bradycardia (heart rate of 50 or less); second- or third-degree AV block; right-sided heart failure owing to pulmonary hypertension; Printzmetal's angina; significant diagnosed cardiomegaly; sick sinus syndrome; peripheral vascular disease
Patients with significant liver dysfunction (known cirrhosis, Bilirubin level>2); Patients with renal failure, measured by creatinine level >1.5; Patients with significant heart failure (NYHA functional class 3 or Higher); bradycardia (heart rate of 50 or less); second- or third-degree AV block; right-sided heart failure owing to pulmonary hypertension; Printzmetal's angina; significant diagnosed cardiomegaly; sick sinus syndrome; peripheral vascular disease
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06839144 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 85 years or younger and at least 20 years old.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages